|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
5 November 2012 |
|
Main ID: |
NCT00465244 |
|
Date of registration:
|
23/04/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Seizure Therapy With Intravenous Levetiracetam and Lorazepam
STILL |
|
Scientific title:
|
Seizure Therapy With Intravenous Levetiracetam and Lorazepam |
|
Date of first enrolment:
|
January 2008 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
http://clinicaltrials.gov/show/NCT00465244 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Joshua N. Goldstein, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Massachusetts General Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- seizure
Exclusion Criteria:
- pregnancy
- renal failure
- hepatic impairment
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Seizures
|
|
Intervention(s)
|
|
Drug: Levetiracetam 1 g IV + Lorazepam 2 mg IV
|
|
Drug: Placebo + Lorazepam 3 mg IV
|
|
Primary Outcome(s)
|
|
Mental status
[Time Frame: hours]
|
|
Respiratory depression
[Time Frame: hours]
|
|
seizure recurrence
[Time Frame: hours]
|
|
Seizures
[Time Frame: hours]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|